s**********e
发帖数: 2888 | 1 记得去年在Science上面看到报道，现在都已经快批准了，牛。
http://news.yahoo.com/us-regulators-fast-track-novel-leukemia-t
Washington (AFP) - US regulators on Monday put an experimental immunotherapy
agent on the fast track to market approval, after 89 percent of leukemia
patients in early trials saw their cancers disappear.
The personalized immunotherapy known as CTL019 was developed by the
University of Pennsylvania and was designated a "breakthrough therapy" by
the US Food and Drug Administration.
That means the experimental therapy will benefit from a speedier than
average review process and will get extra attention from the FDA toward
development for market.
It is the first cancer immunotherapy to receive the breakthrough designation
, and only the fifth biologic agent so far.
The approach works by extracting a patient's T-cells, then genetically
programming them in the lab to target cancer cells that produce a protein
called CD19.
The altered T-cells are then re-injected into the patient's body, where they
multiply and attack cancer.
Researchers reported last year that of 27 patients, including 22 children
and five adults, with acute lymphoblastic leukemia, 89 percent had a
complete response to the therapy, meaning their cancer became undetectable.
The first child to receive the treatment, Emily Whitehead, in May marked two
years of being in remission, and the first adult patient has been in
remission for one year.
"Our early findings reveal tremendous promise for a desperate group of
patients, many of whom have been able to return to their normal lives at
school and work after receiving this new, personalized immunotherapy," said
the Penn research team's leader, Carl June.
The university in 2012 teamed up with pharmaceutical company Novartis to
develop and license personalized chimeric antigen receptor (CAR) T cell
therapies for the treatment of cancers.
In addition to the ongoing trials for acute lymphoblastic leukemia, trials
using CTL019 began in the summer of 2010 in patients with relapsed and
refractory chronic lymphocytic leukemia.
It is also being tried in patients with non-Hodgkin lymphoma and myeloma.
More research is also under way into CAR therapies for mesothelioma, ovarian
, breast and pancreatic cancers. |
s**a
发帖数: 2138 | 2 cd19 在哪些细胞上表达啊？ 挺厉害
immunotherapy
【在 s**********e 的大作中提到】
: 记得去年在Science上面看到报道，现在都已经快批准了，牛。
: http://news.yahoo.com/us-regulators-fast-track-novel-leukemia-t
: Washington (AFP) - US regulators on Monday put an experimental immunotherapy
: agent on the fast track to market approval, after 89 percent of leukemia
: patients in early trials saw their cancers disappear.
: The personalized immunotherapy known as CTL019 was developed by the
: University of Pennsylvania and was designated a "breakthrough therapy" by
: the US Food and Drug Administration.
: That means the experimental therapy will benefit from a speedier than
: average review process and will get extra attention from the FDA toward
|
s**********e
发帖数: 2888 | 3 我觉得最有意义的研究，就是如何生物可以产业化的研究，这样大批的生物人员可以消
化掉。相反，那些只有理论意义或者几年几十年几百年后也许可以转化的研究，除了发
表更多的文章，就是吸引更多的无知少年少女进入这个火坑行业。 |
s**a
发帖数: 2138 | 4 我知道国内一回国哥们现在每个月8500rmb，上海，博士
【在 s**********e 的大作中提到】
: 我觉得最有意义的研究，就是如何生物可以产业化的研究，这样大批的生物人员可以消
: 化掉。相反，那些只有理论意义或者几年几十年几百年后也许可以转化的研究，除了发
: 表更多的文章，就是吸引更多的无知少年少女进入这个火坑行业。
|
s**********e
发帖数: 2888 | 5 这个高还是低？
【在 s**a 的大作中提到】
: 我知道国内一回国哥们现在每个月8500rmb，上海，博士
|
A******y
发帖数: 2041 | 6 Yup, I guess we only have AML and MM to worry about in a few years. Brian
Druker (CML) and Carl June (CLL) will probably win Nobel prize together in a
few years, or they can win individually.
immunotherapy
【在 s**********e 的大作中提到】
: 记得去年在Science上面看到报道，现在都已经快批准了，牛。
: http://news.yahoo.com/us-regulators-fast-track-novel-leukemia-t
: Washington (AFP) - US regulators on Monday put an experimental immunotherapy
: agent on the fast track to market approval, after 89 percent of leukemia
: patients in early trials saw their cancers disappear.
: The personalized immunotherapy known as CTL019 was developed by the
: University of Pennsylvania and was designated a "breakthrough therapy" by
: the US Food and Drug Administration.
: That means the experimental therapy will benefit from a speedier than
: average review process and will get extra attention from the FDA toward
|
d*p
发帖数: 534 | 7 谨慎，还有些问题需要解决，最近有两个病人的治疗过程中在骨髓里面出了问题。 |
E*****e
发帖数: 417 | 8 Impressive. We need more research like this. |
r******g
发帖数: 600 | 9 Car Therapy is very impressive and promosing. Cytokine storm syndromes were
potential problems for patients receiving CAR. In initial clinical trials,
administration of tocilizumab and enbrel was very effective.
Keep in mind that Gleevec from Novartis are expiring in 2 years. Rituximab
for treating patients with ALL-B cell is in phase III. Novartis businessmen
are trying to advertise a new promosing therapy to keep making more money.
To be honest, while CAR may not work as good as Gleevec or Rituximab, but
businessmen will always figure out a way to let patients buying.
It's promising anyway.
【在 d*p 的大作中提到】
: 谨慎，还有些问题需要解决，最近有两个病人的治疗过程中在骨髓里面出了问题。
|
a*********n
发帖数: 2526 | 10 depends on if you have a house there
【在 s**********e 的大作中提到】
: 这个高还是低？
|
